Cormorant Asset Management, LP Replimune Group, Inc. Transaction History

Cormorant Asset Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$28.5 - $39.37 $3.56 Million - $4.92 Million	-125,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$23.5 - $52.65 $2.94 Million - $6.58 Million	125,000 New	125,000 $4.77 Million
Q1 2019 May 15, 2019	SELL	$10.26 - $16.24 $4.8 Million - $7.6 Million	-467,792 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.99 - $22.14 $7.01 Million - $10.4 Million	467,792 New	467,792 $7.53 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $605M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.